TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,844.16−0.12%FTSE ADX9,784.72+0.02%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100166,193.75+0.14%DFM:EMIRATESNBDAED 31.30−0.63%ADX:IHCAED 352.00+0.00%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 300.15+0.23%Gold$4,120.94−0.48%Brent$110.85+1.49%BTC$81,639.78−0.25%ETH$2,394.16−0.46%DFM General5,844.16−0.12%FTSE ADX9,784.72+0.02%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100166,193.75+0.14%DFM:EMIRATESNBDAED 31.30−0.63%ADX:IHCAED 352.00+0.00%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 300.15+0.23%Gold$4,120.94−0.48%Brent$110.85+1.49%BTC$81,639.78−0.25%ETH$2,394.16−0.46%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralOpen 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Closed 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Open

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Atara Biotherapeutics Inc · Overview · TradingHolo

Markets › United States › NAS › ATRA

A

Atara Biotherapeutics Inc

NAS:ATRAHealthcarenasdaq_composite

$8.96−2.40%At closeAt close · Tue 20 Oct · ≈ AED 32.91 · Market cap $89.94M · Next earnings Thu 29 Oct

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

1D

−2.4%

1M

−7.5%

3M

+3.8%

6M

+79.6%

1Y

−41.2%

Why it's moving today

No company news in the last day; the move tracks its market and sector.

ATRA −2.40% today

✦ This week in three lines

No written digest yet for ATRA. The figures on this page are the source when one is written.

Financials

USD millions · annual5Y CAGR —

Valuation

P/E vs sector2.8× vs −1.7×

Price / Book vs sector−2.3× vs 2.0×

Price / Sales vs sector0.7× vs 4.0×

Price / Free cash flow vs sector−1.8× vs −1.5×

cheap for itself (2.0×)expensive for itself (5.7×)

Forecasts

3 buy1 hold0 sell4 analysts

Average target$0.0000 −100.0%

Analysts0

EPS surprises, last 85 beats

Dividends

Yield0.0%

Annual payout—

Payout ratio0.0%

Next ex-date—

Years of growth—

Latest news

All ATRA news →

BUAtara Biotherapeutics Reports that the Resubmitted Tabelecleucel (Tab-cel®) Biologics License Application Has Been Accepted by the U.S. Food and Drug Administration

BusinessWire · 6 d ago

TRAtara Biotherapeutics, Inc. (ATRA) FDA Accepts Tab-cel BLA; PDUFA Set for Mar 31, 2027

TradingView · 6 d ago

TRAtara Biotherapeutics, Inc. (ATRA) Partner Resubmits Tab-cel BLA to FDA

TradingView · 20 d ago

Key facts

At close · Tue 20 Oct

Market cap (USD)$89.94M

P/E2.8×

Dividend yield0.0%

52-week range$3.92 – $19.15

Avg volume (20d)35,530

Shares outstanding10,037,700

Beta0.09

Short interest4.6% of float

Next earningsThu 29 Oct

Radar Score

—

Value—

Quality—

Momentum—

Income—

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral…

Sector

Healthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

—−1.33%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

—−0.69%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

—−0.96%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

—+1.36%